Anthrax

New type of anthrax vaccine moves into larger-scale trial

Published in TB and Outbreaks Week, May 11th, 2004

A potentially safer vaccine to protect against anthrax is moving into a larger-scale clinical trial following a successful pilot study conducted at St. Louis University School of Medicine and three other sites.

Researchers at St. Louis University's Center for Vaccine Development and its clinical research organization, SoLUtions, are preparing to conduct a phase II human study of a new investigational anthrax vaccine developed by VaxGen, Inc.

"The goal is to develop an anthrax vaccine with better protection, an improved safety profile and a simpler dosing schedule," said Geoffrey J. Gorse, MD, principal investigator for the study and professor of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2004-05-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry